Results 31 to 40 of about 54,207 (313)

Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells

Neoplasia: An International Journal for Oncology Research, 2012
Epidermal growth factor receptor (EGFR) is an important oncoprotein that promotes cell growth and proliferation. Dasatinib, a bcr-abl inhibitor, has been approved clinically for the treatment of chronic myeloid leukemia and demonstrated to be effective ...
Yu-Chin Lin, Meng-Hsuan Wu, Tzu-Tang Wei, Shu-Hui Chung, Kuen-Feng Chen, Ann-Lii Cheng, Ching-Chow Chen   +6 more
doaj   +1 more source

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

JAMA Oncology, 2020
Importance A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive ...
S. Shen, Xiaojuan Chen, J. Cai, Jie Yu, Ju Gao, Shaoyan Hu, X. Zhai, Changda Liang, X. Ju, Hua Jiang, R. Jin, Xue-dong Wu, Ningling Wang, Xin Tian, K. Pan, Hui Jiang, Lirong Sun, Yongjun Fang, Chi-kong Li, Q. Hu, Minghua Yang, Yiping Zhu, Hui Zhang, Chunfu Li, Deqing Pei, S. Jeha, Jun J. Yang, Cheng Cheng, Jingyan Tang, Xiaofan Zhu, C. Pui   +30 more
semanticscholar   +1 more source

Prediction of drug–drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling

Cancer Chemotherapy and Pharmacology, 2022
Recent in vitro studies demonstrated that dasatinib inhibits organic cation transporter 2 (OCT2), multidrug and toxin extrusion proteins (MATEs), and organic anion transporting polypeptide 1B1/1B3 (OATP1B1/1B3).
Ming Chang, S. Bathena, L. Christopher, Hong Shen, A. Roy   +4 more
semanticscholar   +1 more source

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency

HemaSphere, 2018
. Dasatinib is an ABL1 tyrosine kinase inhibitor (TKI) with a short in vivo plasmatic half-life but with good efficiency, which is not fully understood.
Kelly Airiau, Béatrice Turcq, Stéphane Bouchet, Elodie Laharanne, Jean-Philippe Vial, Gabriel Etienne, François-Xavier Mahon, Francis Belloc   +7 more
doaj   +1 more source

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

Science Translational Medicine, 2019
Dasatinib is a pharmacologic switch for CARs that enables physicians to control CAR T cell function in real time. Putting CAR T cells in idle Chimeric antigen receptor, or CAR, T cells can be an effective cell therapy for cancer.
K. Mestermann, Theodoros Giavridis, Justus Weber, Julian Rydzek, Silke Frenz, T. Nerreter, Andreas Mades, M. Sadelain, H. Einsele, M. Hudecek   +9 more
semanticscholar   +1 more source

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion

Journal of Hematology & Oncology, 2021
Relapses of CD19-expressing leukemia in patients who achieved initial remission after CART cell treatment have been reported to correlate with poor CART cells persistence.
Hao Zhang, Yong-xian Hu, Mi Shao, Xinyi Teng, Penglei Jiang, Xiujian Wang, Hui Wang, Jiazhen Cui, Jian Yu, Zuyu Liang, L. Ding, Yingli Han, Jieping Wei, Yulin Xu, Xiaoqing Li, W. Shan, Jimin Shi, Yi Luo, P. Qian, He Huang   +19 more
semanticscholar   +1 more source

FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway [PDF]

, 2017
Deregulated SRC/FAK signaling leads to enhanced migration and invasion in many types of tumors. In myxoid and round cell liposarcoma (MRCLS), an adipocytic tumor characterized by the expression of the fusion oncogene FUS-CHOP, SRC have been found as one ...
González, M. Victoria, Hermida Prado, Francisco, Singh Singh, Ranjit, Tornin Cavielles, Juan   +3 more
core   +2 more sources

Dasatinib targets c-Src kinase in cardiotoxicity

Toxicology Reports, 2023
Dasatinib is a multitargeted kinase inhibitor used for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. Unfortunately, treatment of cancer patients with some kinase inhibitors has been associated with cardiotoxicity.
Manar Elmadani, Sami Raatikainen, Orvokki Mattila, Tarja Alakoski, Jarkko Piuhola, Pirjo Åström, Olli Tenhunen, Johanna Magga, Risto Kerkelä   +8 more
doaj  

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia

Cancer Medicine, 2021
Background We investigated the feasibility of the clinical application of non‐invasive transthoracic echocardiography for diagnosis of pulmonary arterial hypertension induced by dasatinib (D‐PAH) in chronic myeloid leukemia (CML).
Sung‐Eun Lee, Jee Hyun Kong, Soo‐Hyun Kim, Eun‐Jung Jang, Nack‐Gyun Chung, Bin Cho, Suk Joong Oh, Hae‐Eok Jung, Ho‐Joong Youn, Woo‐Baek Chung, Dong‐Wook Kim   +10 more
doaj   +1 more source

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Journal for ImmunoTherapy of Cancer, 2021
Introduction The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved.
E. Redin, I. Garmendia, T. Lozano, D. Serrano, Yaiza Senent, M. Redrado, Maria Villalba, Carlos E. De Andrea, F. Expósito, D. Ajona, S. Ortiz-Espinosa, A. Remírez, C. Bértolo, C. Sainz, J. García-Pedrero, R. Pio, J. Lasarte, J. Agorreta, L. Montuenga, A. Calvo   +19 more
semanticscholar   +1 more source